Literature DB >> 20571548

Chagas disease: pushing through the pipeline.

Julie Clayton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20571548     DOI： 10.1038/nature09224

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  9 in total

1.  Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain.

Authors:  José Muñoz; Oriol Coll; Teresa Juncosa; Mireia Vergés; Marta del Pino; Victoria Fumado; Jordi Bosch; Elizabeth J Posada; Sara Hernandez; Roser Fisa; Josep Maria Boguña; Montserrat Gállego; Sergi Sanz; Montserrat Portús; Joaquim Gascón
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

2.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

Authors:  Jose Antonio Marin-Neto; Anis Rassi; Carlos A Morillo; Alvaro Avezum; Stuart J Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf
Journal:  Am Heart J       Date:  2008-07       Impact factor: 4.749

3.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Authors:  María-Jesús Pinazo; Gerard Espinosa; Montserrat Gállego; Paulo Luis López-Chejade; Julio A Urbina; Joaquim Gascón
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

4.  In vitro and in vivo experimental models for drug screening and development for Chagas disease.

Authors:  Alvaro José Romanha; Solange Lisboa de Castro; Maria de Nazaré Correia Soeiro; Joseli Lannes-Vieira; Isabela Ribeiro; André Talvani; Bernadette Bourdin; Bethania Blum; Bianca Olivieri; Carlos Zani; Carmenza Spadafora; Egler Chiari; Eric Chatelain; Gabriela Chaves; José Eduardo Calzada; Juan Manuel Bustamante; Lucio H Freitas-Junior; Luz I Romero; Maria Terezinha Bahia; Michel Lotrowska; Milena Soares; Sonia Gumes Andrade; Tanya Armstrong; Wim Degrave; Zilton de Araújo Andrade
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-03       Impact factor: 2.743

5.  Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.

Authors:  Gustavo Benaim; John M Sanders; Yael Garcia-Marchán; Claudia Colina; Renee Lira; Aura R Caldera; Gilberto Payares; Cristina Sanoja; Juan Miguel Burgos; Annette Leon-Rossell; Juan Luis Concepcion; Alejandro G Schijman; Mariano Levin; Eric Oldfield; Julio A Urbina
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

6.  Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors.

Authors:  Dayse T Silva; Maria de Nazareth S L de Meirelles; Danielle Almeida; Julio A Urbina; Mirian Claudia S Pereira
Journal:  Int J Antimicrob Agents       Date:  2006-05-18       Impact factor: 5.283

7.  Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease.

Authors:  A E Paniz-Mondolfi; A M Pérez-Alvarez; G Lanza; E Márquez; J L Concepción
Journal:  Chemotherapy       Date:  2009-05-19       Impact factor: 2.544

8.  Ergosterol biosynthesis and drug development for Chagas disease.

Authors:  Julio A Urbina
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

9.  A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.

Authors:  Patricia S Doyle; Yuan M Zhou; Juan C Engel; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191
  9 in total
  55 in total

1.  Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.

Authors:  Xiaohua Zhu; Qiang Liu; Sihyung Yang; Toufan Parman; Carol E Green; Jon C Mirsalis; Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Chad E Stephens; Moloy Banerjee; Abdelbasset A Farahat; Manoj Munde; W David Wilson; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.

Authors:  Frederick S Buckner; Maria Terezinha Bahia; Praveen Kumar Suryadevara; Karen L White; David M Shackleford; Naveen Kumar Chennamaneni; Matthew A Hulverson; Joy U Laydbak; Eric Chatelain; Ivan Scandale; Christophe L M J Verlinde; Susan A Charman; Galina I Lepesheva; Michael H Gelb
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

3.  Evidence of ternary complex formation in Trypanosoma cruzi trans-sialidase catalysis.

Authors:  Isadora A Oliveira; Arlan S Gonçalves; Jorge L Neves; Mark von Itzstein; Adriane R Todeschini
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

Review 4.  Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

Authors:  Galina I Lepesheva; Fernando Villalta; Michael R Waterman
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

5.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

Authors:  Frederick S Buckner; Julio A Urbina
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12       Impact factor: 4.077

6.  Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Marcel Kaiser; Eric Chatelain; Jean-Robert Ioset
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

7.  Trypanosoma cruzi Calreticulin Topographical Variations in Parasites Infecting Murine Macrophages.

Authors:  Andrea González; Carolina Valck; Gittith Sánchez; Steffen Härtel; Jorge Mansilla; Galia Ramírez; María Soledad Fernández; José Luis Arias; Norbel Galanti; Arturo Ferreira
Journal:  Am J Trop Med Hyg       Date:  2015-03-09       Impact factor: 2.345

8.  Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Paul W Alexander; Jason H Chaplin; Martine Keenan; Susan A Charman; Catherine J Perez; Michael R Waterman; Eric Chatelain; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

Review 9.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

10.  Genetic variation of North American Triatomines (Insecta: Hemiptera: Reduviidae): initial divergence between species and populations of Chagas disease vector.

Authors:  Bertha Espinoza; Jose Alejandro Martínez-Ibarra; Guiehdani Villalobos; Patricia De La Torre; Juan Pedro Laclette; Fernando Martínez-Hernández
Journal:  Am J Trop Med Hyg       Date:  2012-12-18       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.